Pregled bibliografske jedinice broj: 1065467
Representation of CYP3A4, CYP3A5 and UGT1A4 polymorphisms within Croatian breast cancer patients’ population
Representation of CYP3A4, CYP3A5 and UGT1A4 polymorphisms within Croatian breast cancer patients’ population // International journal of environmental research and public health, 17 (2020), 10; 3692, 11 doi:10.3390/ijerph17103692 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 1065467 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Representation of CYP3A4, CYP3A5 and UGT1A4 polymorphisms within Croatian breast cancer patients’ population
Autori
Bojanić, Kristina ; Kuna, Lucija ; Bilić Ćurčić, Ines ; Wagner, Jasenka ; Smolić, Robert ; Kralik, Kristina ; Kizivat, Tomislav ; Ivanac, Gordana ; Včev, Aleksandar ; Wu, George Y. ; Smolić Martina
Izvornik
International journal of environmental research and public health (1661-7827) 17
(2020), 10;
3692, 11
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
single nucleotide polymorphism ; drug metabolizing enzyme ; breast cancer therapy ; anastrozole ; side effects
Sažetak
Single nucleotide polymorphism (SNP) in genes encoding drug-metabolizing enzymes (DME) could have a critical role in individual responses to anastrozole. Frequency of CYP3A4*1B, CYP3A5*3 and UGT1A4*2 SNPs in 126 Croatian breast cancer (BC) patients and possible association with anastrozole-induced undesirable side effects were analyzed. Eighty-two postmenopausal patients with estrogen receptor (ER)-positive BC treated with anastrozole and 44 postmenopausal ER-positive BC patients before hormonal adjuvant therapy were included in the study. Genomic DNA was genotyped by TaqMan Real-Time PCR. Bone mineral density (BMD) was measured by dual-energy X-ray absorptiometry. The homozygotes for the variant G allele of CYP3A5*3 were predominant (88%), and the homozygotes for the reference A allele were not detected. While homozygotes for the variant G allele of CYP3A4*1B were not detected, predominantly wild type homozygotes for A allele (94%) were present. CYP3A4*1B and CYP3A5*3 SNPs were in 84.3% linkage disequilibrium (D’ = 0.843) and 95.1% (D’ = 0.951) in group treated with anastrozole and w/o treatment, respectively. Homozygotes for the A allele of UGT1A4*2 were not detected in our study groups. Although the variant CYP3A5*3 allele, which might result in poor metabolizer phenotype and more pronounced side effects, was predominant, significant association with BMD changes induced by anastrozole were not confirmed.
Izvorni jezik
Engleski
Znanstvena područja
Temeljne medicinske znanosti, Kliničke medicinske znanosti
POVEZANOST RADA
Ustanove:
Medicinski fakultet, Zagreb,
Klinički bolnički centar Osijek,
Klinička bolnica "Dubrava",
Medicinski fakultet, Osijek,
Fakultet za dentalnu medicinu i zdravstvo, Osijek
Profili:
Robert Smolić
(autor)
Gordana Ivanac
(autor)
Ines Bilić-Ćurčić
(autor)
Tomislav Kizivat
(autor)
Jasenka Wagner
(autor)
Lucija Kuna Roguljić
(autor)
Kristina Bojanić
(autor)
Aleksandar Včev
(autor)
Kristina Kralik
(autor)
Martina Smolić
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- Social Science Citation Index (SSCI)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE